Joe & Ali Torre Lead ‘Two Against One’ Prostate Cancer Campaign

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 9 No 11
Volume 9
Issue 11

NEW YORK-To help support spouses of prostate cancer patients, New York Yankees manager Joe Torre, a prostate cancer survivor, and his wife Ali are helping to launch “Two Against One: Couples Battling Prostate Cancer.” This multimedia program helps spouses become more informed about prostate cancer and empowers them to advocate for improved outcomes for their husbands.

NEW YORK—To help support spouses of prostate cancer patients, New York Yankees manager Joe Torre, a prostate cancer survivor, and his wife Ali are helping to launch “Two Against One: Couples Battling Prostate Cancer.” This multimedia program helps spouses become more informed about prostate cancer and empowers them to advocate for improved outcomes for their husbands.

The program was developed with the prostate cancer advocacy group US TOO! International, Inc., the American Foundation for Urologic Disease, and an alliance of prominent medical urologists and oncologists. Biotechnology companies Amgen and Praecis Pharmaceuticals are sponsoring the program.

The physical effects of prostate cancer may strike only men, but research shows that the emotional impact of the disease can be even greater for their wives.

That doesn’t stop wives from playing a key role in their husband’s prostate cancer care—approximately one in four men with prostate cancer say their treatment decision was made either solely by their wife/partner or equally with them, according to results of a national survey by Roper Starch Worldwide.

The new “Two Against One” program consists of a website that leads spouses through the trauma of diagnosis, treatment, and beyond. It also features links to other useful resources. This information has been captured in a free printed booklet.

Also available is a new educational video, “Not By Myself,” featuring singers Billy Davis, Jr., and Marilyn McCoo, another famous couple that has successfully faced prostate cancer.

The booklet and video are available by calling toll-free 877-550-9624. The “Two Against One” website is found at http://www.2against1.com.

Recent Videos
Immunotherapy-based combinations may elicit a synergistic effect that surpasses monotherapy outcomes among patients with muscle-invasive bladder cancer.
Hosts Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, discuss presentations at ESMO 2025 that may impact bladder, kidney, and prostate cancer care.
Biochemical markers and advanced imaging modalities play a critical role in monitoring patients undergoing RLT therapy for metastatic prostate cancer.
Data support the use of radioligand therapy in combination with androgen receptor pathway inhibitors to optimize prostate cancer outcomes.
Experts weigh in on tumor-informed testing, false positives, relevant trial data, and other key concepts related to circulating tumor DNA.
Ongoing studies in kidney cancer aim to explore determinants of immune-related adverse effects and strategies for mitigating them.
Machine learning-based approaches may play a role in further understanding of how somatic alterations influence responses or resistance to therapy.
Data from a first-in-disease trial assessing a personalized cancer vaccine in RCC require validation at a larger level, according to David Braun, MD, PhD.
Related Content